研究

Iwahashi N, Ikezaki M, Komohara Y, Fujiwara Y, Noguchi T, Nishioka K, Sakai K, Nishio K, Ueda M, Ihara Y, Uchimura K, Ino K, Nishitsuji K.

Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis

Watanabe S, Sakai K, Matsumoto N, Koshio J, Ishida A, Abe T, Ishikawa D, Tanaka T, Aoki A, Kajiwara T, Koyama K, Miura S, Goto Y, Sekiya T, Suzuki R, Kushiro K, Fujisaki T, Yanagimura N, Ohtsubo A, Shoji S, Nozaki K, Saida Y, Yoshizawa H, Nishio K, Kikuchi T.

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, Ando N, Sonomura K, Kojima S, Taketsuna M, Kim YH, Yoshida H, Ozasa H, Sakamori Y, Hirano T, Matsuda F, Hirai T, Nishio K, Sakagami T, Fukushima M, Nakanishi Y, Honjo T, Okamoto I.

Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer

Okamoto W, Sakai K, Makiyama A, Yamamoto Y, Shitara K, Denda T, Izawa N, Nakano Y, Nishina T, Esaki T, Hara H, MiuraY, Boku N, Yamazaki K, Hironaka S, Misumi T, Hyodo I, Muro K, Nishio K.

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

Hayashi Y, Fujita K, Sakai K, Adomi S, Banno E, Nojima S, Tomiyama E, Matsushita M, Kato T, Hatano K, Kawashima A, Minami T, Morii E, Uemura H, Nishio K, Nonomura N.

Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer.

Kanemura H, Hayashi H, Tomida S, Tanizaki J, Suzuki S, Kawanaka Y, Tsuya A, Fukuda Y, Kaneda H, Kudo K, Takahama T, Imai R, Haratani K, Chiba Y, Otani T, Ito A, Sakai K, Nishio K, Nakagawa K.

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC

Nagai S, Nishihara H, Suzuki T, Nishio K, Taniguchi H, Tsuchihara K, Nakamura K, Takamatsu R, Ueno T, Aburatani H, Kohno T, Kohsaka S.

Recommendations related to the analytical equivalence assessment of gene panel testing

Hayashi H, Yonesaka K, Nakamura A, Fujimoto D, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Hataji O, Yano Y, Hirano K, Daga H, Okada H, Chiba Y, Sakai K, Nishio K, Yamamoto N, Nakagawa K.

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)

Makutani Y, Sakai K, Yamada M, Wada T, Chikugo T, Satou T, Iwasa Y, Yamamoto H, de Velasco MA, Nishio K, Kawamura J.

Performance of Idylla™ RAS-BRAF mutation
test for formalin-fixed paraffin-embedded tissues of colorectal cancer

Nishio M, Nishio K, Reck M, Garon EB, Imamura F, Kawaguchi T, Yamaguchi H, Ikeda S, Hirano K, Visseren-Grul C, Ceccarelli M, Wijayawardana SR, Zimmermann A, Matsui T, Enatsu S, Nakagawa K.

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC.

Nozaki K, Watanabe S, Nishio K, Sakai K, Kikuchi T.

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report

Khandakar GI, Satoh R, Takasaki T, Fujitani K, Tanabe G, Sakai K, Nishio K, Sugiura R.

ACAGT-007a, an ERK MAPK
Signaling Modulator, in Combination with AKT Signaling Inhibition Induces
Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells

Maekawa M, Taniguchi T, Nishio K, Sakai K, Matsushita K, Nakatani K, Ishige T, Ikejiri M, Nishihara H, Sunami K, Yatabe Y, Hatanaka KC, Hatanaka Y, Yamamoto Y, Fukuyama K, Oda S, Saito K, Yokomura M, Kubo Y, Sato H, Tanaka Y, Fuchioka M, Yamasaki T, Matsuda K, Kurachi K, Funai K, Baba S, Iwaizumi M.

Precision cancer genome testing needs proficiency testing involving all stakeholders

Kaibori M, Sakai K, Matsushima H, Kosaka H, Matsui K, De Velasco MA, Sekimoto M, Nishio K.

Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period

Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, Nakagawa K

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)